Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Botulinum toxin with unique makeup compares to market leader
As the popularity of botulinum toxins for both cosmetic and therapeutic applications continues to grow, so too does development of new techniques and formulations. IncobotulinumtoxinA (Xeomin, Merz), the newest of the toxin formulations, is a promising product that according to clinical studies exhibits similar efficacy to onabotulinumtoxinA (Botox, Allergan), despite having a distinctly different biological makeup.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
